Our top pick for
Long-term investors
Urovant Sciences Ltd is a biotechnology business based in the US. Urovant Sciences shares (UROV) are listed on the NASDAQ and all prices are listed in US Dollars. Urovant Sciences employs 70 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Urovant Sciences
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – UROV – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Urovant Sciences stock price (NASDAQ: UROV)
Use our graph to track the performance of UROV stocks over time.Urovant Sciences shares at a glance
Information last updated 2021-05-23.
| 52-week range | $16.11 - $16.26 |
|---|---|
| 50-day moving average | $16.21 |
| 200-day moving average | $13.98 |
| Wall St. target price | $16.17 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-3.92 |
Buy Urovant Sciences shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Urovant Sciences stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Urovant Sciences financials
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -75.13% |
| Return on equity TTM | 0% |
| Profit margin | 0% |
| Book value | $0.78 |
| Market capitalisation | $531.8 million |
TTM: trailing 12 months
Urovant Sciences share dividends
We're not expecting Urovant Sciences to pay a dividend over the next 12 months.
Urovant Sciences share price volatility
Over the last 12 months, Urovant Sciences's shares have ranged in value from as little as $16.11 up to $16.26. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Urovant Sciences's is 2.3354. This would suggest that Urovant Sciences's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Urovant Sciences overview
Urovant Sciences Ltd. , a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions in the United States. The company's lead product candidate is vibegron, an oral small molecule beta-3 agonist for the treatment of overactive bladder (OAB), OAB in men with benign prostatic hyperplasia, and abdominal pain due to irritable bowel syndrome. It is also developing URO-902, a gene therapy for patients with OAB who have failed oral pharmacological therapy. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017.
Urovant Sciences in the news
Frequently asked questions
What percentage of Urovant Sciences is owned by insiders or institutions?Currently 71.346% of Urovant Sciences shares are held by insiders and 19.213% by institutions. How many people work for Urovant Sciences?
Latest data suggests 70 work at Urovant Sciences. When does the fiscal year end for Urovant Sciences?
Urovant Sciences's fiscal year ends in March. Where is Urovant Sciences based?
Urovant Sciences's address is: 11-12 Street, James?s Square, London, United Kingdom, SW1Y 4LB What is Urovant Sciences's ISIN number?
Urovant Sciences's international securities identification number is: BMG9381B1081 What is Urovant Sciences's CUSIP number?
Urovant Sciences's Committee on Uniform Securities Identification Procedures number is: G9381B108
More guides on Finder
-
Melania Trump has an NFT — what to know before you buy
Melania Trump launched an NFT platform — you can buy an image of her eyes.
-
Vigorus (VIS) price prediction
Read our expert analysis on Vigorus and how the token will perform in the future.
-
Today’s top U.S. stocks: Mechel Pao ADRs (MTL ↑8.1%), Sibanye-Stillwater Limited (SBSW ↑7.4%)
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
-
How to order free at-home COVID tests today — but note, there’s a wait
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
-
Dogecoin jumps 10% on word you can use it to buy Tesla merch
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
-
Today’s top U.S. stocks: Las Vegas Sands (LVS ↑15.3%), Wynn Resorts Limited (WYNN ↑9.1%)
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
-
Thursday’s top U.S. stocks: Taiwan Semiconductor Manufacturing Company Ltd. (TSM ↑8.4%), Lam Research Corporation (LRCX ↑6.1%)
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
-
Donut savings review
Donut earns up to 10% APY, but you must have an iOS device.
-
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
-
Is Berkshire Hathaway the next $1 trillion stock?
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Ask an Expert